CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0110
-0.0005 (-4.35%)
At close: Jul 17, 2026
CERo Therapeutics Holdings Employees
CERo Therapeutics Holdings had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$11,994,797
Market Cap
520.44K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - | 8 | 0 |
| Dec 31, 2024 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2023 | 9 | - | - | 8 | 1 |
CERo Therapeutics Holdings News
- 4 weeks ago - CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment - GlobeNewsWire
- 2 months ago - CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial - GlobeNewsWire
- 3 months ago - CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial - GlobeNewsWire
- 3 months ago - CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial - GlobeNewsWire
- 4 months ago - CERo Therapeutics Provides Shareholder Update - GlobeNewsWire
- 5 months ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 5 months ago - CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient - GlobeNewsWire
- 6 months ago - CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML - GlobeNewsWire